In Well-Treated Celiac Patients Low-Level Mucosal Inflammation Predicts Response to 14-day Gluten Challenge

Area of Science:

• Immunology
• Gastroenterology
• Proteomics

Background:

• Celiac disease (CeD) involves gluten-triggered immune responses damaging the small intestine.
• Histology grades CeD severity, and a gluten-free diet is the standard treatment.
• Gluten challenges assess diagnosis and drug efficacy but show variable patient responses.

Purpose of the Study:

• To investigate the baseline inflammatory and immune status in well-treated celiac disease patients before a gluten challenge.
• To determine if low-level inflammation and antigluten immunity exist in patients on a gluten-free diet.
• To assess the sufficiency of histological evaluation for confirming mucosal healing in CeD.

Main Methods:

• Proteome analysis of duodenal biopsies from 19 treated CeD patients before and after a 14-day gluten challenge.
• Analysis of total tissue and isolated epithelial cell compartments.
• Assessment of gluten-specific CD4+ T-cell frequencies and blood inflammatory markers.

Main Results:

• Patients with a strong mucosal response to gluten challenge exhibited pre-existing low-level tissue inflammation.
• This baseline inflammation correlated with increased gut gluten-specific CD4+ T-cells and a subtle blood inflammatory profile.
• Histological assessment alone was insufficient to identify all patients with ongoing gut inflammation.

Conclusions:

• Apparently well-treated celiac disease patients often harbor persistent low-grade gut inflammation and antigluten immunity.
• Histology may underestimate the extent of mucosal recovery and healing in CeD.
• The findings raise concerns about the universal efficacy of a gluten-free diet in completely suppressing gut inflammation in all CeD patients.